Unknown EARLY_PHASE1 INTERVENTIONAL 1-arm NCT03661554

BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma (BCMA CAR-T)

BCMA Nano Antibody CAR-T Cells for the Treatment of Refractory Relapsed Multiple ,Single Center, Single Arm and Open Clinical Study of Myeloma

Sponsor: Henan Cancer Hospital

Conditions Relapsed and Refractory Multiple Myeloma

Interventions BCMA CAR-T Cells

Updated 5 times since 2018 Last updated: Sep 6, 2018 Started: Apr 10, 2018 Primary completion: Oct 30, 2018 Completion: Nov 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Relapsed and Refractory Multiple Myeloma and is currently ongoing. Henan Cancer Hospital leads this study, which shows 5 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown EARLY_PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status EARLY_PHASE1
Oct 2020 — Jan 2021 [monthly]

Unknown Status EARLY_PHASE1

Status: Recruiting → Unknown Status
Oct 2018 — Oct 2020 [monthly]

Recruiting EARLY_PHASE1

First recorded

Apr 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Henan Cancer Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd.

Data source: The Pregene (ShenZhen) Biotechnology Company, Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shenzhen, China